Abstract
Five years of sustained indoor residual spraying (IRS) of insecticide from 2014 to 2019, first using a carbamate followed by an organophosphate, was associated with a marked reduction in the burden of malaria in five districts of Uganda. We assessed malaria burden over an additional 21 months, corresponding to a change in IRS formulations using clothianidin with and without deltamethrin and the start of the COVID-19 pandemic. We document an unprecedented resurgence in malaria burden: in years 4-5 of sustained IRS cases were 84% lower than the pre-IRS period, in year 6 this increased to a 43% reduction, and in the first 9 months of year 7, cases were 39% higher than pre-IRS levels. The timing of this resurgence corresponded to a change of active ingredient to clothianidin, a new IRS active ingredient. Further research is needed to determine mechanisms leading to this resurgence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institutes of Health as part of the International Centers of Excellence in Malaria Research (ICMER) program (U19AI089674). Funding for this work was also supported by the National Institute of Allergy and Infectious Diseases (F31AI150029).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of University of California, San Francisco waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at https://github.com/aeepstein/resurgence-irs-uganda
